Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Patents

Acquisition of Patents
6 Months Ended
Nov. 30, 2017
Acquisition of Patents

Note 7 – Acquisition of Patents

As discussed in Note 9 below, the Company consummated an asset purchase on October 16, 2012, and paid $3,500,000 for certain assets, including intellectual property, certain related licenses and sublicenses, FDA filings and various forms of the PRO 140 drug substance. The Company followed the guidance in Financial Accounting Standards Topic 805 to determine if the Company acquired a business. Based on the prescribed accounting, the Company acquired assets and not a business. As of November 30, 2017, the Company has recorded and is amortizing $3,500,000 of intangible assets in the form of patents. The Company estimates the acquired and enforceable patents have an estimated life of 10 years. Subsequent to the acquisition date, the Company has continued to expand, amend and file patent applications central to its current clinical trial strategies, which, in turn, have extended the protection period for certain methods of using PRO 140 and formulations comprising PRO 140 out through at least 2026 and 2038, respectively, in various countries.


The following presents intangible assets activity:


     November 30, 2017      May 31, 2017  

Gross carrying amounts

   $ 3,500,000      $ 3,500,000  

Accumulated amortization

     (1,793,808      (1,618,770







Total amortizable intangible assets, net

     1,706,192        1,881,230  

Patents currently not amortized

     35,989        35,989  







Carrying value of intangibles, net

   $ 1,742,181      $ 1,917,219  







Amortization expense related to patents was approximately $87,500 and $175,000 for the three and six months ended November 30, 2017 and 2016. The estimated aggregate future amortization expense related to the Company’s intangible assets with finite lives is estimated at approximately $350,000 per year for the next five years.